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Conclusion: Stent length in SES implantation for CTO was not associated with long-
term cardiac death and ST. The use of longer stent may increase the risk of TVR.
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Background: Subintimal tracking and reentry (STAR) technique has been proposed
in case of failure to cross coronary occlusion (CTO) with conventional approaches.
However concerns on periprocedural myocardial infarction (pMI) and stent thrombosis
(ST) risk have been raised.
Methods: One-hundred-forty-four patients with CTO were treated by STAR technique
in our Institution since March 2004. Successful STAR recanalization (defined as TIMI
3 final flow in the main vessel and in the major side branches) was reached in 93
patients (64.5%), which represent the population of the current study. The decision to
perform elective stenting was left to the operator’s discretion. pMI was defined as an
increase in cardiac biomarkers >3 time above the ULN. All patients were re-evaluated
by coronary angiography within 3 months. ST was defined according to the ARC
criteria. Major adverse event (MACE) at 1 year included death and MI.
Results: Elective stenting was performed in 55 patients (Stent group) whereas POBA
was done in 38 patients (POBA group). The most important clinical and angiographic
characteristics were similar in the 2 groups. The length of the subintimal vessel segment
was shorter in the Stent group (72±35 mm vs 89±33 mm; p = 0.026). Final stent length
was 59±27 mm. pMI occurred more often in the Stent group (50% vs 26%; p = 0.022;
OR = 5.27; 95% CI = 1.15-6.82). Reocclusion at angiographic follow-up was observed
in 14% Stent group and 21% in the POBA group (p = 0.24). ST occurred in 1 patient
(1.8%). MACE at 1 year occurred in 52% in the Stent group and in 26.5% in the POBA
group (p = 0.014) (Figure).
Conclusion: Elective stenting increases the risk of pMI following successful CTO
recanalization by the STAR technique
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Background: To investigate the impact of multivessel disease (MVD) with and
without a concurrent chronic total occlusion (CTO) in a non-infarct related artery (IRA)
on post-procedural myocardial blush grade (MBG) and three-year mortality in patients
with ST-segment elevation myocardial infarction (STEMI) undergoing primary
percutaneous coronary intervention (PCI).
Methods: In the HORIZONS-AMI trial, 3,602 STEMI pts were randomized to
different anticoagulation and stent strategies. Angiographic core lab assessment of the
extent of pre-intervention angiographies coronary artery disease was available in all
patients who underwent primary PCI (n=3,548). Patients were classified as having
single vessel disease (SVD, n=1563, 44%), MVD without a CTO (n=1688, 47.6%), or
a CTO in a non-IRA (n=297, 8%). We investigated post-procedural MBG and early
(<30 days) and late (30 days-3 years) mortality.
Results: Patients with MVD and a CTO in a non-IRA were significantly more likely
to have post-PCI MBG 0/1 compared patients with MVD without a CTO and those
with SVD (12.1% vs. 6.8% vs. 8.0% respectively, p=0.02). MVD with a CTO in a non-
IRA was associated with increased mortality between 0 to 30 days and from 30 days
to 3 years after the index event (Figure 1). After multivariate analysis, a CTO in a non-
IRA was an independent predictor of both early (HR 2.62, 95% CI 1.25-5.50, p=0.01)
and late mortality (HR 1.97, 95% CI 1.19-3.25, p<0.01), while MVD without a CTO
was only a predictor of early mortality (HR 2.20, 95% CI 1.26-3.83, p<0.01).
Conclusion: In this large-scale contemporary multicenter prospective randomized trial,
a CTO in a non-IRA was associated with a higher incidence of MBG 0/1 and
significantly increased early and late mortality. MVD without a CTO was only
associated with increased early mortality.
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Background: Chronic total occlusions (CTO) remain a challenge to treat for
interventional cardiologists not only due to lower acute procedural success but also
higher long-term TLR and MACE rates than non-CTO lesions.
Methods: We compared the performance of biolimus eluting biodegradable polymer
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